Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myeloma

被引：21

作者：

Einsele, H. ^{[1
]}

Knop, S. ^{[1
]}

Vogel, M. ^{[2
]}

Mueller, J. ^{[3
]}

Kropff, M. ^{[4
]}

Metzner, B. ^{[5
]}

Langer, C. ^{[6
]}

Sayer, H. ^{[7
]}

Jung, W. ^{[8
]}

Duerk, H. A. ^{[9
]}

Salwender, H. ^{[10
]}

Wandt, H. ^{[11
]}

Bassermann, F. ^{[12
]}

Gramatzki, M. ^{[13
]}

Roesler, W. ^{[14
]}

Wolf, H-H ^{[15
]}

Brugger, W. ^{[16
]}

Engelhardt, M. ^{[17
]}

Fischer, T. ^{[18
]}

Liebisch, P. ^{[6
]}

Straka, C. ^{[19
]}

机构：

[1] Julius Maximilians Univ Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany

[2] Janssen Cilag GmbH, Neuss, Germany

[3] Acromion GmbH, Frechen, Germany

[4] Univ Klinikum Munster, Munster, Germany

[5] Klinikum Oldenburg Klin Onkol & Hamatol, Oldenburg, Germany

[6] Univ Klinikum Ulm, Zentrum Innere Med, Ulm, Germany

[7] Univ Hosp Jena, Jena, Germany

[8] Onkol Univ Med Gottingen, Gottingen, Germany

[9] St Marien Hosp Hamm Knappenstr, Hamm, Germany

[10] Asklepios Klin Altona, Hamburg, Germany

[11] Med Klin 5 Hamatol & Onkol, Nurnberg, Germany

[12] Tech Univ Munich, Med Klin, Munich, Germany

[13] Univ Klinikum Schleswig Holstein, Kiel, Germany

[14] Univ Klinkum Erlangen, Erlangen, Germany

[15] Univ Hosp Halle, Halle, Saale, Germany

[16] Schwarzwald Baar Klinikum, Villingen Schwenningen, Germany

[17] Univ Freiburg, Freiburg, Germany

[18] Otto von Guericke Univ, Magdeburg, Germany

[19] Schon Klin Starnberger See, Berg, Germany

来源：

LEUKEMIA | 2017年 / 31卷 / 06期

关键词：

STEM-CELL TRANSPLANTATION; INDUCTION; THERAPY; PHASE-3;

D O I：

10.1038/leu.2017.83

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1463 / 1466

页数：5

共 50 条

[41] Addition of bortezomib improves efficacy of thalidomide/dexamethasone in newly diagnosed patients with multiple myeloma
不详
CLINICAL LYMPHOMA & MYELOMA, 2008, 8 (02): : 78 - 79
[42] Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population
Sorrig, Rasmus
Klausen, Tobias W.
Salomo, Morten
Vangsted, Annette J.
Frolund, Ulf Christian
Andersen, Kristian T.
Klostergaard, Anja
Helleberg, Carsten
Pedersen, Robert S.
Pedersen, Per T.
Helm-Petersen, Sissel
Teodorescu, Elena Manuela
Preiss, Birgitte
Abildgaard, Niels
Gimsing, Peter
PLOS ONE, 2017, 12 (12):
[43] Impact of Race on Progression-Free Survival and Overall Survival in Patients with Multiple Myeloma
Wani, Kashmira
Gutta, Radhika
Mittal, Aayush
Jamil, Maria
Springer, Kylie
Kuriakose, Philip
BLOOD, 2023, 142
[44] Impact of Duration of Induction Therapy on Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Undergoing Upfront Autologous Stem Cell Transplantation
Chakraborty, Rajshekar
Muchtar, Eli
Kumar, Shaji K.
Buadi, Francis K.
Dingli, David
Dispenzieri, Angela
Haymann, Suzanne
Hogan, William J.
Kapoor, Prashant
Lacy, Martha Q.
Leung, Nelson
Warsame, Rahma
Kourelis, Taxiarchis
Gonsalves, Wilson I.
Gertz, Morie A.
BLOOD, 2017, 130
[45] The Impact of Focal Lesions on Overall and Progression-free Survival in Multiple Myeloma
Kirkizlar, Tugcan Alp
Kirkizlar, Onur
Soyluoglu, Selin
Umit, Elif Gulsum
Ustun, Funda
Demir, Ahmet Muzaffer
INDIAN JOURNAL OF NUCLEAR MEDICINE, 2024, 39 (05): : 353 - 359
[46] Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: a case for response-adapted approach
Lahoud, Oscar B.
Landau, Heather
Nguyen, James
Devlin, Sean
Lendvai, Nikoletta
Weltz, Jonathan
Ayorinde, Tumininu
Chung, David J.
Lesokhin, Alexander M.
Kewalramani, Tarun
Korde, Neha
Mailankody, Sham
Landgren, Ola
Giralt, Sergio
Comenzo, Raymond L.
Hassoun, Hani
LEUKEMIA & LYMPHOMA, 2022, 63 (09) : 2126 - 2135
[47] Impact of autologous stem cell transplantation (ASCT) on progression free survival (PFS) in newly diagnosed multiple myeloma patients (NDMM) with high risk cytogenetic abnormalities
Guman, Tomas
Sykora, Jan
BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY, 2024, 125 (01): : 9 - 11
[48] Thalidomide added to standard therapy improves survival in newly diagnosed multiple myeloma
不详
ONCOLOGY-NEW YORK, 2006, 20 (12): : 1486 - 1486
[49] Superior Complete Response Rate and Progression-Free Survival after Autologous Transplantation with up-Front Velcade-Thalidomide-Dexamethasone Compared with Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma
Cavo, Michele
Tacchetti, Paola
Patriarca, Francesca
Petrucci, Maria Teresa
Pantani, Lucia
Ceccolini, Michela
Galli, Monica
Di Raimondo, Francesco
Crippa, Claudia
Zamagni, Elena
Tosi, Patrizia
Nami, Franco
Bringhen, Sara
Montefusco, Vittorio
Offidani, Massimo
Buttignol, Silvia
Levi, Anna
Gorgone, Ausilia
Brioli, Annamaria
Pallotti, Maria Caterina
Spadano, Tonino
Pescosta, Norbert
Baldini, Luca
Ledda, Antonio
Caravita, Tommaso
Falcone, Antonietta
Zaccaria, Alfonso
Perrone, Giulia
Petrucci, Alessandro
Palumbo, Antonio
Boccadoro, Mario
Baccarani, Michele
BLOOD, 2008, 112 (11) : 65 - 65
[50] Multivariable Analyses of Prognostic Factors for Progression-Free Survival (PFS) and Complete Response (CR) with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial
Hassoun, Hani
Jacobus, Susanna J.
Richardson, Paul G.
Zonder, Jeffrey A.
Voorhees, Peter M.
Kaufman, Jonathan L.
Yee, Andrew J.
Scott, Emma C.
Torka, Pallawi
Libby, Edward
Reeves, Brandi
Wang, Michael L.
Anderson, Larry D., Jr.
Milner, Carter
Gasparetto, Cristina J.
Agha, Mounzer
Khan, Abdullah
Hurd, David Duane
Avigan, David
Costello, Caitlin
Jakubowiak, Andrzej
Lonial, Sagar
Raje, Noopur
Medvedova, Eva
McCarthy, Philip L.
Orlowski, Robert Z.
Nadeem, Omar
Laubach, Jacob P.
Pasquini, Marcelo C.
Giralt, Sergio A.
Masone, Kelly
Samur, Mehmet K.
Perrot, Aurore
Moreau, Philippe
Avet-Loiseau, Herve
Weller, Edie A.
Munshi, Nikhil C.
Anderson, Kenneth C.
BLOOD, 2022, 140 : 4834 - 4838

← 1 2 3 4 5 →